内皮GATA4通过阻止血管分泌信号致病性转换调控肝纤维化与再生
本研究在成年小鼠内皮特异性敲除Gata4,导致肝窦内皮细胞毛细血管化及促纤维化血管分泌信号转换,引起肝窦周围纤维化、肝病和再生受损;CDAA饮食模型和人类肝硬化数据均显示GATA4抑制、MYC激活及PDGFB表达增加。内皮GATA4通过染色质水平抑制MYC激活和促纤维化血管分泌信号保护肝脏,GATA4/MYC/PDGFB/PDGFRβ轴是肝纤维化防治的潜在靶点。
要点
- 内皮细胞Gata4缺失导致小鼠肝窦周围纤维化、肝病和肝再生受损。
- GATA4缺失诱导MYC激活和PDGFB表达,驱动促纤维化血管分泌信号转换。
- 人肝硬化肝组织中GATA4阳性肝窦内皮细胞及其靶基因减少,MYC靶基因包括PDGFB富集。
核心结论
- 内皮GATA4通过在染色质水平抑制MYC激活和促纤维化血管分泌信号,防止肝窦周围纤维化。
- 靶向GATA4/MYC/PDGFB/PDGFRβ轴是预防和治疗肝纤维化的有前景策略。
研究设计与样本
- 研究使用成年Clec4g-icretg/0xGata4fl/fl(Gata4LSEC-KO)小鼠,肝窦内皮细胞特异性敲除Gata4。
- 肝脏通过组织学、电子显微镜、免疫组化/免疫荧光、原位杂交分析,并分离肝窦内皮细胞进行基因表达谱、ChIP测序和ATAC测序。
- 进行部分肝切除术评估再生,使用胆碱缺乏L-氨基酸限定(CDAA)饮食和慢性四氯化碳暴露建立肝纤维化模型。
- 分析人类健康肝脏和肝硬化肝脏的单细胞RNA测序数据以评估内皮改变。
主要发现
- 成年小鼠肝窦内皮细胞Gata4基因缺失导致肝窦周围纤维化、肝病和肝再生受损。
- Gata4缺失伴随肝窦毛细血管化和肝窦内皮细胞向连续内皮转分化,伴有促纤维化血管分泌转换,包括内皮从头表达激活肝星状细胞的细胞因子PDGFB。
- 增加的染色质可及性和激活的MYC介导血管分泌Pdgfb表达。
- CDAA饮食诱导的肝窦周围纤维化与GATA4抑制、MYC激活和肝窦内皮细胞促纤维化血管分泌转换相关,与Gata4LSEC-KO肝脏所见一致。
- CDAA喂养的Gata4LSEC-KO与对照小鼠比较表明内皮GATA4确实防止饮食诱导的肝窦周围纤维化。
临床怎么用
- 作者认为靶向GATA4/MYC/PDGFB/PDGFRβ轴是预防和治疗肝纤维化的有前景策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Angiocrine signaling by liver sinusoidal endothelial cells (LSECs) regulates hepatic functions such as growth, metabolic maturation, and regeneration. Recently, we identified GATA4 as the master regulator of LSEC specification during development. Herein, we studied the role of endothelial GATA4 in the adult liver and in hepatic pathogenesis. METHODS: We generated adult Clec4g-icretg/0xGata4fl/fl (Gata4LSEC-KO) mice with LSEC-specific depletion of Gata4. Livers were analyzed by histology, electron microscopy, immunohistochemistry/immunofluorescence, in situ hybridization, and LSECs were isolated for gene expression profiling, ChIP- and ATAC-sequencing. Partial hepatectomy was performed to assess regeneration. We used choline-deficient, l-amino acid-defined (CDAA) diet and chronic carbon tetrachloride exposure to model liver fibrosis. Human single cell RNA-seq data sets were analyzed for endothelial alterations in healthy and cirrhotic livers. RESULTS: Genetic Gata4 deficiency in LSECs of adult mice caused perisinusoidal liver fibrosis, hepatopathy and impaired liver regeneration. Sinusoidal capillarization and LSEC-to-continuous endothelial transdifferentiation were accompanied by a profibrotic angiocrine switch involving de novo endothelial expression of hepatic stellate cell-activating cytokine PDGFB. Increased chromatin accessibility and amplification by activated MYC mediated angiocrine Pdgfb expression. As observed in Gata4LSEC-KO livers, CDAA diet-induced perisinusoidal liver fibrosis was associated with GATA4 repression, MYC activation and a profibrotic angiocrine switch in LSECs. Comparison of CDAA-fed Gata4LSEC-KO and control mice demonstrated that endothelial GATA4 indeed protects against dietary-induced perisinusoidal liver fibrosis. In human cirrhotic livers, GATA4-positive LSECs and endothelial GATA4 target genes were reduced, while non-LSEC endothelial cells and MYC target genes including PDGFB were enriched. CONCLUSIONS: Endothelial GATA4 protects against perisinusoidal liver fibrosis by repressing MYC activation and profibrotic angiocrine signaling at the chromatin level. Therapies targeting the GATA4/MYC/PDGFB/PDGFRβ axis offer a promising strategy for prevention and treatment of liver fibrosis. LAY SUMMARY: The liver vasculature is supposed to play a major role in the development of liver fibrosis and cirrhosis, which can lead to liver failure and liver cancer. Herein, we discovered that structural and transcriptional changes induced by genetic deletion of the transcription factor GATA4 in the hepatic endothelium were sufficient to cause liver fibrosis. Activation of the transcription factor MYC and de novo expression of the "angiocrine" growth factor PDGFB were identified as downstream drivers of fibrosis and as potential therapeutic targets for this potentially fatal disease.
引用
- Winkler M, Staniczek T, Kürschner SW, et al. Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling. J Hepatol. 2020. PMID: 32916216. doi:10.1016/j.jhep.2020.08.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。